BNTC

BNTC

USD

Benitec Biopharma Inc. Common Stock

$15.710+0.380 (2.479%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$15.330

الأعلى

$15.770

الأدنى

$14.550

الحجم

0.13M

أساسيات الشركة

القيمة السوقية

412.4M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.05M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $9.1الحالي $15.710الأعلى $17.15

أخبار ذات صلة

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.

عرض المزيد
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
Analyst Upgrades

Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.

عرض المزيد
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted

عرض المزيد
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based

عرض المزيد
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines

عرض المزيد
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.